NEPA for nausea prevention during T-DXd in advanced HER2+ or HER2-low breast cancer
Part of Cancer clinical trials.
This trial tests whether the anti-nausea combination NEPA (netupitant and palonosetron) can prevent nausea and vomiting caused by the targeted therapy T-DXd in people with advanced HER2-positive or HER2-low breast cancer. It may help you if you are about to start T-DXd for the first time and want to manage treatment side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 20 years old or older.
- You must have advanced breast cancer (spread or not removable by surgery) that is HER2-positive or HER2-low.
- You need to be starting your first cycle of T-DXd (trastuzumab deruxtecan) therapy.
- You must be willing to take the anti-nausea medication NEPA as prescribed.
- You should not have had nausea or vomiting in the week before starting T-DXd, and must not have brain or spinal cord lining metastases.
- You must agree to use highly effective birth control (unless you cannot become pregnant) and not be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at nausea and vomiting caused by a breast cancer treatment called T-DXd. It aims to understand these side effects and help manage them better.
This trial tests a medicine called IV NEPA (fosnetupitant/palonosetron) to prevent nausea and vomiting in children who are receiving strong chemotherapy. Patients will receive at least one cycle of chemotherapy that is highly likely to cause these side effects.
This study tests whether the medication NEPA (Netupitant and Palonosetron) can prevent nausea and vomiting in people who have had surgery for liver, gallbladder, or pancreatic cancer. It may help those who want to avoid post-surgery sickness.
This trial tests a combination of two drugs, T-DXd (a targeted therapy) and an immunotherapy, before surgery for people with early-stage breast cancer that has low levels of HER2 and is hormone receptor positive. The goal is to see if this treatment can shrink the tumor or eliminate cancer cells before surgery.
This trial studies whether palonosetron helps prevent nausea and vomiting caused by chemotherapy that has a moderate risk of vomiting. It may help you feel more comfortable during chemo and avoid treatment interruptions from severe nausea.
This trial tests if Akynzeo (a nausea medicine) helps prevent vomiting during chemotherapy for endometrial cancer. It is for people starting chemo for the first time.
Hear when a new Patients With HER2-positive Advanced Breast Cancer Treated With T-DXd trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.